Kenya’s marathon champion Peres Jepchirchir provisionally banned by AIU

Peres Jepchirchir has been provisionally suspended after an adverse analytical finding for EPO. The sample was collected in Kenya before her Sydney Marathon victory in August. EPO is banned because it can boost red-blood-cell production and potentially improve endurance. The finding has therefore raised questions about the fairness of her result and her eligibility to compete.

The AIU said the test was conducted out of competition. Jepchirchir won the women’s Sydney race in 2:18:31, finishing more than three minutes ahead of Irine Cheptai. Her agent, Gianni Demadonna, said he felt terrible and believed an athlete using performance-enhancing drugs should be disqualified.

The suspension is provisional, not a final ruling. Sydney organisers said Jepchirchir is entitled to due process and would not comment further until the case concludes. A final outcome could affect her competition status and results, depending on the anti-doping process and its findings.

EPO, or erythropoietin, is a hormone that signals the body to make more red blood cells. Those cells carry oxygen from the lungs to working muscles. More oxygen delivery can support prolonged, demanding exercise, which is especially relevant in marathon running. The article identifies EPO as a banned blood booster.

In competitive sport, using EPO can change an athlete’s normal blood profile through an artificial method. That can improve endurance rather than reflecting only training, talent, and natural physiology. It may also create medical dangers, because thicker blood can place extra strain on circulation. The source specifically states that EPO boosts red-blood-cell production.

Jepchirchir’s case shows why testing matters. An out-of-competition sample collected before her Sydney win returned an adverse analytical finding for EPO. The positive finding has triggered a provisional suspension, while the athlete remains entitled to due process before any final penalty is decided.

Jepchirchir’s Sydney victory was decisive. She finished in 2:18:31 and pulled more than three minutes clear of second-placed compatriot Irine Cheptai. The margin made her dominance clear in a race now under scrutiny because the sample linked to her provisional suspension was collected before the win.

The 33-year-old had already built an exceptional career. She won Olympic gold at the Tokyo Games in 2021 and held the half-marathon world record. She was also a four-time World Marathon Majors winner. Her major marathon victories came in New York in 2021, Boston in 2022, London in 2024, and Sydney in 2026.

Those achievements explain the significance of the case for marathon running. Jepchirchir is not a little-known entrant but a leading champion. If the anti-doping process confirms a violation, her Sydney result and possibly other consequences would be considered under the applicable rules.

EPO changes the blood’s oxygen-delivery system by stimulating production of red blood cells. These cells carry oxygen from the lungs to muscles. During a marathon, muscles need a steady oxygen supply for a prolonged period. Increasing that supply can potentially support endurance and delay fatigue, which is why EPO is relevant to distance running.

The mechanism is straightforward: EPO sends a signal that encourages the body to make more oxygen-carrying cells. With more carriers available, more oxygen can reach working muscles with each circulation of the blood. This can create an artificial performance advantage rather than an advantage gained solely through training. The article describes EPO as a banned blood booster.

Jepchirchir’s out-of-competition sample returned an adverse analytical finding for EPO before her Sydney victory. That finding led to a provisional suspension, but it does not by itself establish a final rule violation. The case must proceed through due process before sporting consequences are settled.

An adverse analytical finding is a laboratory result indicating a prohibited substance or marker in an athlete’s sample. It is an important anti-doping signal, but it is not automatically the final legal conclusion. In Jepchirchir’s case, the AIU said her out-of-competition sample returned such a finding for EPO.

The result allowed the AIU to impose a provisional suspension while the matter is examined. The athlete can receive information about the finding, challenge the case through the applicable process, and present a response. Anti-doping procedures can also involve confirmation and a hearing before a final decision. These procedural details reflect established anti-doping practice; the article itself specifically emphasizes due process.

Sydney organisers said Jepchirchir is entitled to due process and would make no further comment until the process concludes. Therefore, the current suspension should not be treated as a final penalty. The eventual decision will determine whether a rule violation is confirmed and what sanctions, if any, follow.

A confirmed anti-doping violation could put Jepchirchir’s Sydney result at risk. The most immediate possible consequence would be disqualification from the race, which could remove her winning position and any medal, title, or prize linked to it. Her result could then be revised, subject to the governing rules and final decision.

The article provides a clear example of how timing can matter. Ruth Chepngetich received a three-year ban after admitting violations involving hydrochlorothiazide, a prohibited diuretic. Her world record of 2:09:56 remained on the books because she set it before her positive test. That example shows that records are not automatically erased in every case.

Jepchirchir’s final consequences are not yet known. Her agent said an athlete who uses performance-enhancing drugs should be disqualified, while Sydney organisers stressed due process. If the violation is confirmed, authorities would decide the status of her Sydney result and any related medals, titles, or records under the applicable rules.

Red blood cells are the blood’s main oxygen carriers. They collect oxygen in the lungs and transport it through the bloodstream to muscles. During prolonged exercise, muscles repeatedly need oxygen to keep producing energy. A greater supply can help the body support sustained work over a long distance.

In a marathon, the heart and circulation deliver oxygen continuously while the legs work for more than two hours. If more red blood cells are available, the blood can carry more oxygen in each circulation. That can support aerobic energy production and help an athlete maintain a demanding pace. This is the basic reason EPO’s effect matters in endurance sport.

The article states that EPO boosts red-blood-cell production and calls it a banned blood booster. Jepchirchir’s sample returned an adverse analytical finding for EPO. Her provisional suspension reflects concern about a possible artificial change to oxygen delivery, although the final case still requires due process.